Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• 5'-[N-(d-biotinoyl)sulfamoyl]amino-5'-deoxyadenosine (Bio-AMS) selectively inhibits Mycobacterium tuberculosis biotin protein ligase (MtBPL), arresting lipid biosynthesis.
• Mycobacterium tuberculosis develops resistance to Bio-AMS via overexpression of the type II sulfatase Rv3406, which inactivates the drug.

Purpose of the Study:

• To design and synthesize novel nucleoside analogs of Bio-AMS that circumvent Rv3406-mediated resistance.
• To evaluate the potency and antimycobacterial activity of these new analogs against resistant strains.

Main Methods:

• Chemical synthesis of modified nucleoside analogs at the 5'-position.
• Enzyme inhibition assays to determine binding affinity (K_D) to MtBPL.
• Antimycobacterial activity testing (MIC) against Mtb H37Rv and Rv3406 overexpression strains.
• Metabolism assays using recombinant Rv3406 and resistance frequency determination.

Main Results:

• New analogs retained subnanomolar potency against MtBPL (K_D = 0.66-0.97 nM).
• The 5' R-C-methyl derivative (compound 6) showed potent antimycobacterial activity (MIC = 1.56 μM) against wild-type and resistant Mtb strains.
• Compound 6 was not metabolized by recombinant Rv3406, and resistance to it was not observed (frequency <1.4 × 10^-10).

Conclusions:

• Strategic modification of the 5'-position successfully prevented enzymatic inactivation by Rv3406.
• Compound 6 represents a promising lead compound for overcoming Rv3406-mediated resistance in Mycobacterium tuberculosis infections.